<DOC>
	<DOCNO>NCT01282541</DOCNO>
	<brief_summary>Epiphora excessive tearing significant disability many affect patient diminish quality life . There grow consensus injection Botulinum Toxin A ( BTX-A ) lacrimal gland provide relief patient hyperlacrimation secondary aberrant regeneration 7th nerve , limited evidence might help reduce normal tear production patient epiphora anatomic functional outflow obstruction . BTX-A inject transconjunctivally palpebral lobe lacrimal gland transcutaneously orbital lobe . Both delivery rout successful symptom relief minimal complication . However , effectiveness transconjunctival versus transcutaneous injection systematically compare . Also , whether incidence side effect related dosage , concentration , location injection unknown also systematically study . The investigator plan conduct randomized clinical trial patient functional tear compare transcutaneous delivery route BTX-A transconjunctival delivery route ( common route described literature ) . The investigator also compare side effect profile delivery route .</brief_summary>
	<brief_title>Determination Optimum Delivery Route Botulinum Toxin A Patients With Epiphora</brief_title>
	<detailed_description />
	<mesh_term>Lacrimal Apparatus Diseases</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>age 18 year ability give inform consent symptom epiphora set either patent lacrimal outflow system obstruct outflow system patient desire surgical therapy poor surgical candidate pregnancy ocular motility abnormality prior ptosis , and/or strabismus surgery 2 mm preexist ptosis inability give inform consent history bleed disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Tearing , Epiphora , Botulinum Toxin A</keyword>
</DOC>